Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224718 | 0.87 | MEN1 (0.42) | MEN1KMT2ASLC6A9GAASLC6A5 | |
| SCHEMBL25337002 | 0.86 | L3MBTL1 (0.49) | MEN1KMT2AGAA | |
| SCHEMBL29571284 | 0.86 | L3MBTL1 (0.49) | MEN1KMT2AGAA | |
| SCHEMBL4224760 | 0.84 | LMNA (0.54) | MEN1KMT2AGAAP2RX1P2RX7 | |
| SCHEMBL16053638 | 0.84 | ACP1 (0.44) | MEN1KMT2AGAAACP1 | |
| SCHEMBL4232294 | 0.83 | GPR35 (0.46) | MEN1KMT2A | |
| SCHEMBL30203791 | 0.81 | MEN1 (0.77) | MEN1KMT2AALDH1A1 | |
| SCHEMBL375021 | 0.81 | MEN1 (0.77) | MEN1KMT2AALDH1A1 | |
| SCHEMBL13019006 | 0.79 | KMT2A (0.56) | MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL13919660 | 0.79 | MEN1 (0.48) | MEN1KMT2ASLC6A9EGFRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-20120004273-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | AHMAD NADIA MAMOONA (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20120004273-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | AHMAD NADIA MAMOONA (GB) | 2012-01-05 | — | — | US | disclosed |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA UK LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA UK LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
| US-20100317704-A1 | SPIRO-CONDENSED IMIDAZOLONE DERIVATIVES INHIBITING THE GLYCINE TRANSPORTER | Glaxo Group Limited a corporation | 2010-12-16 | — | — | US | disclosed |
| US-20100317704-A1 | SPIRO-CONDENSED IMIDAZOLONE DERIVATIVES INHIBITING THE GLYCINE TRANSPORTER | Glaxo Group Limited a corporation | 2010-12-16 | — | — | US | disclosed |
| WO-2008092878-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092878-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092873-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2007104775-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104776-A1 | N-PHENYL-2-0X0-1,4-DIAZASPIR0 [4.5] DEC-3-EN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | WO | disclosed |
| EP-1719770-A2 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| EP-1320529-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-05-24 | — | — | EP | disclosed |
| US-20040053928-A1 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-18 | — | — | US | disclosed |
| EP-1320529-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002024684-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053928-A1 | Quinoline derivatives as antibacterials | AAAS, QDPR, QARS1 | MEN1 3636/4885KMT2A 3673/4885SLC6A9 4129/4885 |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | MEN1 3425/4885KMT2A 1666/4885SLC6A9 3762/4885 |
| US-20120004273-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SLC1A2, SLC1A1, SLC18A2 | MEN1 3279/4885KMT2A 1147/4885SLC6A9 92/4885 |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | MEN1 1667/4885KMT2A 1780/4885SLC6A9 2993/4885 |
| US-20100317704-A1 | SPIRO-CONDENSED IMIDAZOLONE DERIVATIVES INHIBITING THE GLYCINE TRANSPORTER | SLC6A5, SLC6A7, SLC6A3 | MEN1 2463/4885KMT2A 2422/4885SLC6A9 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.